<DOC>
	<DOCNO>NCT00234026</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine , work different way stop growth cancer cell , either kill cell stop dividing . PURPOSE : This phase II trial study well gemcitabine work treat patient newly diagnose , relapse , chemotherapy-resistant mantle cell lymphoma .</brief_summary>
	<brief_title>Gemcitabine Treating Patients With Newly Diagnosed , Relapsed , Chemotherapy-Resistant Mantle Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine efficacy gemcitabine , term objective response tolerability , patient newly diagnose , relapse , chemotherapy-resistant mantle cell lymphoma . Secondary - Determine time progression time treatment failure patient treat drug . - Determine response duration patient treat drug . - Determine adverse reaction patient treated drug . OUTLINE : This multicenter study . Patients receive gemcitabine IV 30 minute day 1 8 . Treatment repeat every 3 week 9 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 1 year , every 6 month 1 year , annually 3 year . PROJECTED ACCRUAL : A total 10-29 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm mantle cell lymphoma meet 1 follow criterion : Newly diagnose Chemotherapy resistant Relapsed disease 2 prior line chemotherapy Measurable disease At least 1 unidimensionally measurable lesion ≥ 11 mm CT scan No prior current CNS lymphoma lymphomatous meningosis PATIENT CHARACTERISTICS : Age 18 Performance status WHO 01 Life expectancy Not specify Hematopoietic Neutrophil count ≥ 1,500/mm^3 ( 1,000/mm^3 case bone marrow infiltration ) Platelet count ≥ 100,000/mm^3 ( 75,000/mm^3 case bone marrow infiltration ) Hepatic Bilirubin ≤ 2 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2 time ULN AST ALT ≤ 2 time ULN No active hepatitis Renal Creatinine clearance ≥ 50 mL/min Cardiovascular No congestive heart failure No New York Heart Association class III IV heart disease No unstable angina pectoris No significant cardiac arrhythmia arrhythmia require chronic treatment No myocardial infarction within past 3 month Immunologic No active autoimmune disease No ongoing infection ( e.g. , HIV ) Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 12 month study participation No malignancy within past 5 year except nonmelanoma skin cancer adequately treat carcinoma situ cervix No uncontrolled diabetes mellitus No gastric ulcer No uncontrolled medical condition would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent thalidomide Chemotherapy See Disease Characteristics Endocrine therapy Not specify Radiotherapy Prior radiotherapy allow provided indicator lesion irradiate field No concurrent radiotherapy lung mediastinum Surgery Not specify Other More 30 day since prior systemic anticancer treatment More 30 day since prior clinical trial participation No concurrent anticancer drug No concurrent experimental drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
</DOC>